In this scenario, biotech companies have developed a method for engineering and growing functional organs, such as hearts, lungs, livers, and kidneys, in a lab. These engineered organs are identical to natural ones, and can be implanted into patients without the need for immunosuppressive drugs. The technology has advanced to the point where the supply of engineered organs is unlimited, putting an end to organ transplant waiting lists.
As a result, hospitals and clinics now have a steady and reliable source of organs for transplantation, and can perform the surgeries on-demand. This greatly increases the number of organ transplants that can be performed each year, and many more lives are saved as a result.
The demand for organ transplants also increases as the procedure becomes more widely available and the risk of rejection is eliminated. Insurance companies start to cover the cost of organ transplants as the procedure becomes the standard of care for end-stage organ failure. The biotech companies that developed the engineered organs become highly profitable, and the market for engineered organs becomes one of the fastest-growing in the healthcare industry. The stock prices of these companies also increases.
In addition, As the technology continues to improve, the cost of producing engineered organs decreases, making them more affordable for patients and healthcare systems. This leads to more widespread access to organ transplants and improved outcomes for patients with end-stage organ failure.
However, like in any technological change, there are also ethical concerns to consider, such as the use of human cells and genetic material in engineered organs, the impact on organ donation, and the cost-benefit trade-offs for patients and healthcare systems.
